Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry.Lai, Y.T., Wang, T., O'Dell, S., Louder, M.K., Schon, A., Cheung, C.S.F., Chuang, G.Y., Druz, A., Lin, B., McKee, K., Peng, D., Yang, Y., Zhang, B., Herschhorn, A., Sodroski, J., Bailer, R.T., Doria-Rose, N.A., Mascola, J.R., Langley, D.R., Kwong, P.D.
(2019) Nat Commun 10: 47-47
- PubMed: 30604750
- DOI: 10.1038/s41467-018-07851-1
- Primary Citation of Related Structures:
- PubMed Abstract:
Diverse entry inhibitors targeting the gp120 subunit of the HIV-1 envelope (Env) trimer have been developed including BMS-626529, also called temsavir, a prodrug version of which is currently in phase III clinical trials. Here we report the character ...
Diverse entry inhibitors targeting the gp120 subunit of the HIV-1 envelope (Env) trimer have been developed including BMS-626529, also called temsavir, a prodrug version of which is currently in phase III clinical trials. Here we report the characterization of a panel of small-molecule inhibitors including BMS-818251, which we show to be >10-fold more potent than temsavir on a cross-clade panel of 208-HIV-1 strains, as well as the engineering of a crystal lattice to enable structure determination of the interaction between these inhibitors and the HIV-1 Env trimer at higher resolution. By altering crystallization lattice chaperones, we identify a lattice with both improved diffraction and robust co-crystallization of HIV-1 Env trimers from different clades complexed to entry inhibitors with a range of binding affinities. The improved diffraction reveals BMS-818251 to utilize functional groups that interact with gp120 residues from the conserved β20-β21 hairpin to improve potency.
Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.,Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, Cambridge, MA, 02142, USA.,Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA. firstname.lastname@example.org.,Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.,Computer Assisted Drug Design, Bristol-Myers Squibb Research and Development, Wallingford, CT, 06492, USA.,Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.,Department of Biology, Johns Hopkins University, Baltimore, MD, 21218, USA.